FierceBiotechIT reports on a survey conducted by Merck, and outlined in a paper in The American Journal of Accountable Care, that judged willingness of patients to have their tumors sequenced and the data studied in exchange for payment. Sixty-three of the 64 patients surveyed were willing to share their data as long as they retained data ownership and only shared the data with the entity that paid for it. “While the model would still involve significant outlay,” the report notes, “the authors think it would be cheaper than assay development.” Meanwhile, the California Supreme Court has agreed to hear a case that would determine whether healthcare regulators violated the state Constitution’s privacy clause when they accessed a local doctor’s prescribing records as part of an investigation into claims of unprofessional conduct.”
Full Story